RxDoctor Payments DataLook up a doctor →

Donald Taylor, MD

Pain Medicine · Marietta, GANPI 1023127875

Payments from drug & device makers

$9,433in general payments, 2019–2025

Across 436 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orexo US, Inc.$1K
  • AbbVie$953
  • Indivior Inc.$864
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$678
  • Hikma Pharmaceuticals USA$673
  • Pfizer$663
  • plus $4K from 43 others

What the payments were for

  • Consulting fees$1,00011%
  • Food & beverage$7,84189%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,433 in reported general payments places this provider in the 85th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$238,584
Medicare patients
213
Services billed
2,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate253$312,788
OxycontinOxycodone Hcl195$248,935
BelbucaBuprenorphine Hcl112$98,712
ZubsolvBuprenorphine Hcl/Naloxone Hcl82$84,891
Nucynta ErTapentadol Hcl39$71,942
Buprenorphine244$62,457
SublocadeBuprenorphine30$62,357
Oxymorphone Hcl ErOxymorphone Hcl40$49,104
LinzessLinaclotide82$46,568
Nurtec OdtRimegepant Sulfate32$45,489
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl234$43,298
NucyntaTapentadol Hcl32$41,486
Fentanyl191$40,102
UbrelvyUbrogepant24$35,633
Oxycodone Hcl1,068$26,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er, Nucynta$288$524,928436 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl$673$119,171830 claims
Indivior Inc.Sublocade, Suboxone$864$86,25966 claims
Orexo US, Inc.Zubsolv$1,313$84,89182 claims
AbbVieLinzess, Ubrelvy$953$82,202106 claims
PfizerNurtec Odt$663$45,48932 claims
MerckBelsomra$222$16,09937 claims
Redhill Biopharma Inc.Movantik$67$12,82627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →